$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

급성관상동맥 증후군 치료를 위한 국내·외 항혈소판제 약물요법 가이드라인 비교 연구
A Comparative Study the USA, Europe and Korea Guidelines of Antiplatelet Therapy for Patients with Acute Coronary Syndrome 원문보기

한국임상약학회지 = Korean journal of clinical pharmacy, v.25 no.3, 2015년, pp.200 - 208  

정은주 (경성대학교 약학대학) ,  이채원 (경성대학교 약학대학) ,  백인환 (경성대학교 약학대학)

Abstract AI-Helper 아이콘AI-Helper

Objective: Patients with acute coronary syndrome (ACS) are typically managed with dual antiplatelet therapy of acetylsalicylic acid (aspirin) and $P2Y_{12}$ receptor inhibitor. In this study, we discussed current and previous antiplatelet therapy guidelines and compared with guidelines of...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • 본 연구에서는 전체적인 흐름을 파악하기 위하여 미국과 유럽 각각의 가이드라인이 개정되어 온 것을 조사하고, 그 이후에 최신 가이드라인과 이전 가이드라인의 비교를 통하여 선진국에서의 ST분절 상승 심근경색증과 불안정 협심증/ST분절 비상승 심근경색증에서의 항혈소판제의 약물요법 가이드라인에 대한 변화를 파악하고자 한다. 더 나아가서는 미국, 유럽,그리고 한국 간의 최신 가이드라인을 비교하고자 한다.
  • 본 연구에서는 전체적인 흐름을 파악하기 위하여 미국과 유럽 각각의 가이드라인이 개정되어 온 것을 조사하고, 그 이후에 최신 가이드라인과 이전 가이드라인의 비교를 통하여 선진국에서의 ST분절 상승 심근경색증과 불안정 협심증/ST분절 비상승 심근경색증에서의 항혈소판제의 약물요법 가이드라인에 대한 변화를 파악하고자 한다. 더 나아가서는 미국, 유럽,그리고 한국 간의 최신 가이드라인을 비교하고자 한다.
  • 이뿐만 아니라, 임상에서 지침으로 쓰이도록 2006년과 2008년에 STEMI와 NSTEMI를 가진 성인환자를 대상으로 임상성과측정(Clinical Performance Measures)을 실시하여 ACC와 AHA에서 발표한 임상진료지침(Clinical practice guidelines)도 있다. 신뢰할만한 증거들을 기반으로 한 이 임상진료지침은 실제 임상에서 환자의 진료나 치료적 측면에서 더 나은 결과를 내고, 의료진들에게 더 발전되고 개선된 의료를 환자에게 제공하고 검증할 목적을 가진다.32,33)
본문요약 정보가 도움이 되었나요?

질의응답

핵심어 질문 논문에서 추출한 답변
급성관상동맥증후군이란? 급성관상동맥증후군(acute coronary syndrome; ACS) 이란, 관상동맥의 혈관 내에 급성으로 크고 작은 혈전이 생겨 이로 인해 순간적인 혈관폐쇄 또는 혈전에서 분비되는 여러 혈관 수축성 물질들이 혈관을 더 심하게 수축시켜 심한 관상동맥폐쇄로 인하여 심장으로의 혈류공급이 부족해져서 생기는 질환이다.1) 심혈관질환은 전 세계적으로 사망원인 1위의 질환이며, 여러 심혈관질환 중에서도 특히나 급성관상동맥증후군은 심혈관질환의 주요 위험요인이다.
급성관상동맥증후군의 치료는 어떤 것들이 있는가? 급성관상동맥증후군의 치료는 크게 4가지로 나뉜다. 허혈증상과 심근손상을 줄이고 예방하기 위한 항허혈 치료, 병태생리에 가장 중요하게 작용하는 항혈전 치료, 환자의 위험도에 따라 관동맥 협착이나 폐색을 해결하기 위한 혈관 재관류요법, 그리고 심혈관계 발작을 줄이기 위한 위험인자 조절과 약물치료가 있다.8) 이 중에서 급성관상동맥증후군의 표준약물치료는 항혈전 치료에 속하는 항혈소판 약물요법이다.
급성관상동맥증후군은 어떻게 나뉘어 지는가? 2) 다시 말해, 급성관상동맥증후군은 심근의 혈액공급 저하에 기인하는 모든 급성 증상, 즉 급성심근허혈(myocardial ischemia)에 기인한 모든 임상증세를 아우르는 광범위한 용어이다.3) 이러한 급성관상동맥증후군은 불안정형 협심증(unstable angina, UA) 과 급성심근경색증으로 나뉠 수 있으며, 급성심근경색증은 다시 ST분절 상승 심근경색증(ST-elevation myocardial infarction, STEMI)과 ST분절 비상승 심근경색증(Non-ST-elevation myocardial infarction, NSTEMI) 로 나뉘어 진다(Fig. 1).
질의응답 정보가 도움이 되었나요?

참고문헌 (57)

  1. Overbaugh, Kristen J. Acute coronary syndrome. AJN 2009;109(5):42-52. 

  2. Yun DD, Alpert JS. Acute coronary syndromes. Cardiology 1997;88:223-37. 

  3. Park SJ. Acute coronary syndrome. Korean Circulation J 1998;28(12):2066-75. 

  4. Molife C, Frech-Tamas F, DeKoven M, et al. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. J Med Econ, in press. 

  5. Fanari Z, Weiss S, Weintraub WS. Cost effectiveness of antiplatelet and antithrombotic therapy in the setting of acute coronary syndrome: current perspective and literature review. Am J Cardiovasc Drugs, in press. 

  6. Kim J, Lee E, Lee T, Sohn A. Economic burden of acute coronary syndrome in South Korea: a national survey. BMC Cardiovasc Disord 2013;13(55):1-8. 

  7. Korsnes JS, Davis KL, Ariely R, et al. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Spec Pharm 2015;21(6):443-50. 

  8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). Circulation. 2007;116:e148-e304. 

  9. Vos GJ, Bennaghmouch N, Qaderdan K, et al. Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J, in press. 

  10. Brener SJ, Maehara A, Mintz GS, et al. Effect of prior aspirin treatment on patients with acute coronary syndromes: insights from the PROSPECT study. J Invasive Cardiol, in press. 

  11. Johnson SG, Gruntowicz D, Chua T, et al. Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention. J Manag Care Spec Pharm 2015;21(7):552-7. 

  12. Wei YQ, Wang DG, Yang H, et al. Cytochrome P450 CYP 2C19*2 Associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PLoS One 2015;10(7):1-8. 

  13. Kim IS, Choi BR, Jeong YH, et al. The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009;7(5):897-9. 

  14. Rollini F, Angiolillo DJ, Cattaneo M. The GRAVITAS study. G Ital Cardiol 2012;13(1):1-5. 

  15. Bavishi C, Panwar S, Messerli FH, et al. Meta-analysis of comparison of the newer oral $P2Y_{12}$ inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-Elevation acute coronary syndrome. Am J Cardiol, in press. 

  16. De Servi S, Goedicke J, Schirmer A, et al. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care 2014;3(4):363-72. 

  17. Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol 2015;22(6):734-42. 

  18. Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2015;169(6):899-905. 

  19. Paramo JA. New era in antiplatelet therapy based on results from recent clinical trials. Med Clin 2011;137(11):504-8. 

  20. Gandhi S, Zile B, Tan MK, et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol 2014;30(12):1725-31. 

  21. Huber K, Lip GY. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thromb Haemost 2013;110(1):11-3. 

  22. AmericanHeartAssociation (http://my.americanheart.org/professional/StatementsGuidelines/ByTopic/TopicsA-C/ACCAHA-Joint-Guidelines_UCM_321694_Article.jsp) 

  23. European Society of Cardiology (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/ESC-Clinical-Practice-Guidelines-list/listing) 

  24. Woo JS, Kim MK. Updates in the management of patients with acute coronary syndrome. Korean J Med 2009;76(6):661-676. 

  25. Korea Society of Interventional Cardiology (http://www.kscvi.org/new_ksic2015/ksic_data/board/lists/page/1/b_id/5) 

  26. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2013;61(4):e78-140. 

  27. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). J Am Coll Cardiol 2009;54(23):2205-2241. 

  28. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2012;60(7):645-681. 

  29. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011;123(18):e426-e579. 

  30. Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33(20):2569-2619. 

  31. Hamm W, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 2011;32(23):2999-3054. 

  32. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on performance measures (writing committee to develop performance measures on ST-elevation and non-ST-elevation myocardial infarction). Circulation 2006;113(5):732-761. 

  33. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for sdults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on performance measures (writing committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction). Circulation 2008;118(24):2598-2648. 

  34. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;62(24):e139-228. 

  35. Kander T, Dankiewicz J, Friberg H, et al. Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study. Crit Care 2014;18(5):495. 

  36. Kander T, Brokopp J, Erlinge D, et al. Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome. Scand J Clin Lab Invest 2015;75(1):27-35. 

  37. Berger JS. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Am J Cardiol 2013;112(5):737-745. 

  38. Xian Y, Wang TY, McCoy LA, et al. Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) Study. Circulation 2015;132(3):174-181. 

  39. Serebruany VL, Pershukov IV. The differences between the guidelines of the European society of cardiology and the American college of cardiology/American heart association for oral $P2Y_{12}$ inhibitor therapy in the management of patients with acute coronary syndromes. Kardiologiia 2013;53(7):70-77. 

  40. Wouter JJ, Collet JP, De Luca L. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Curr Med Res Opin 2012;28(2):203-211. 

  41. Rahman A, Latona J. New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents. Aust Fam Physician 2014;43(12):861-866. 

  42. Htun WW, Steinhubl SR. Ticagrelor: the first novel reversible P2Y(12) inhibitor. Expert Opin Pharmacother 2013;14(2):237-245. 

  43. Serebruany VL, DiNicolantonio JJ. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet $P2Y_{12}$ inhibitors after acute coronary syndromes. Thromb Haemost 2013;110(1):5-10. 

  44. Linn CE, Shah NK, Epstein BJ. Role of CYP450 in antiplatelet therapy: considerations for patients at risk for further cardiovascular or cerebrovascular problems. J Pharm Technol 2013;29(2):72-77. 

  45. Caldeira D, Pinto F, Ferreira J. Dyspnea and reversibility profile of P2Y antagonists: systematic review of new antiplatelet drugs. Am J Cardiovasc Drugs 2014;14(4):303-311. 

  46. Kazi, DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Inter Med 2014;160(4):221-232. 

  47. Yamwong S, Permsuwan U, Tinmanee S, et al. Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand. Health Econ Rev 2014;4(1):17. 

  48. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110(10):1226-30. 

  49. Bahler CK, Hann CR, Fjield T, et al. Second-generation trabecular meshwork bypass stent (iStent inject) increases outflow facility in cultured human anterior segments. Am J Ophthalmol 2012;153(6):1206-13. 

  50. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64(20):2086-97. 

  51. Alexopoulos D, Xanthopoulou I, Plakomyti TE, et al. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis 2012;60(2):332-3. 

  52. Norgard, NB, Dinicolantonio JJ. Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med 2013;125(4):91-102. 

  53. Ticagrelor (Brilinta) - better than clopidogrel (Plavix)? Med Lett Drugs Ther 2011;53(1372):69-70. 

  54. Rafeedheen R, Bliden KP, Liu F, et al. Novel antiplatelet agents in cardiovascular medicine. Curr Treat Options Cardiovasc Med. 2015 Jun;17(6):383. 

  55. Guideline for pharmacotherapy of anti-platelet agent for acute coronary syndrome. Korea Society of Interventional Cardiology (2012) 

  56. Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014;7(6):895-902. 

  57. Oh IY, Park KW, Kang SH, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98(2):139-44. 

저자의 다른 논문 :

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로